CERo Therapeutics has been denied continued listing on Nasdaq due to non-compliance with stockholders' equity requirements. The company plans to appeal the decision, seek OTC Markets trading, and continue clinical operations while exploring financing alternatives.

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share. Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. Here a...